Functional Brands Launches Exclusive GLP-Squared Dual-Peptide Injection on Tru2u.health
Functional Brands launched GLP-Squared Injection, a dual-peptide formulation combining Semaglutide and Tirzepatide, exclusively via its Tru2u.health telehealth platform. The proprietary injection offers clinician-supervised dosing for enhanced appetite regulation, glycemic control, and adipose reduction, positioning the company to capture share in the multi-billion-dollar GLP-1 therapy market.
1. Product Launch
Functional Brands has launched GLP-Squared Injection, combining Semaglutide and Tirzepatide in a single formulation, now available exclusively through its Tru2u.health telehealth platform. The company is offering the injection immediately to qualifying members following clinician evaluation and approval.
2. Mechanism and Clinical Advantages
GLP-Squared leverages Semaglutide’s GLP-1 receptor agonism alongside Tirzepatide’s dual GLP-1/GIP agonist activity to deliver synergistic effects on appetite suppression, glycemic control, and adipose tissue reduction. Clinically calibrated dosing ratios and physician-guided protocols aim to maximize therapeutic outcomes while ensuring individualized safety profiles.
3. Platform Integration and Exclusivity
The formulation is distributed solely via Tru2u.health, Functional Brands’ proprietary digital health platform that manages telehealth consultations, laboratory screenings, prescription fulfillment, and ongoing metabolic coaching. Exclusive access creates a competitive moat by preventing distribution through traditional retail or mail-order pharmacy channels.
4. Market Opportunity
The global GLP-1 therapy market is among the fastest-growing healthcare segments, driven by rising demand for Semaglutide and Tirzepatide treatments in obesity and metabolic disease. GLP-Squared’s differentiated dual-peptide offering positions Functional Brands to capture meaningful share of an expanding multi-billion-dollar market.